Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited has cancelled 140,700 ordinary fully paid shares following the execution of an on-market share buy-back completed on 31 March 2026. The reduction in issued capital may enhance earnings per share and capital efficiency, indicating active capital management that can influence shareholder value and market perception of the stock.
The most recent analyst rating on (AU:NEU) stock is a Hold with a A$12.50 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX under the code NEU. The company is focused on developing pharmaceutical therapies, with its ordinary fully paid shares forming the core of its listed capital structure for investors.
Average Trading Volume: 552,609
Technical Sentiment Signal: Hold
Current Market Cap: A$1.59B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.